Logotype for United Therapeutics Corporation

United Therapeutics (UTHR) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for United Therapeutics Corporation

Q3 2026 earnings summary

4 Nov, 2026

Executive summary

  • Q3 revenue reached a record $832.5M, up 4% YoY; net income fell 24% to $258.6M and diluted EPS declined to $5.71 from $7.16.

  • Commercial momentum and a broad cardiopulmonary and respiratory strategy span 14 development programs, including manufactured-organ alternatives.

Financial highlights

  • Q3 operating income was $307.8M versus $388.5M; operating expenses rose to $524.7M from $411.0M.

  • R&D expense increased 119% to $279.2M, including Thymmune and manufactured-organ and cardiopulmonary spending; SG&A fell to $146.4M, including a $66.5M litigation-accrual reversal.

  • 9M revenue was $2,397.3M versus $2,392.5M; operating income was $964.4M versus $1,135.8M, and net income was $866.5M versus $970.4M.

  • TTM operating cash flow was $1.4B; cash, cash equivalents and marketable investments totaled $3,535.7M at September 30, 2026.

Outlook and guidance

  • Management described the growth outlook as the strongest in its history; expanded commercial resources are expected to support growth in Q4 and 2027.

  • FDA PDUFA dates are April 26, 2027 for nebulized Tyvaso in IPF and June 24, 2027 for oral ralinepag in PAH; ralinepag timing depends on resolving API manufacturing deficiencies.

  • TETON-PPF enrolled 754 patients against a 698-patient target; topline data are expected in 2H 2027.

  • Soft-mist inhaler NDA filing is expected in 2027 after additional data generation; development-partner work is underway to update the timeline.

  • Growth drivers include Tyvaso DPI, increased PH-ILD prescribing, potential ralinepag and IPF launches, Orenitram growth and modest price increases.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from United Therapeutics